Survival after neoadjuvant/induction combination immunotherapy vs combination platinum‐based chemotherapy for locally advanced (Stage <scp>III</scp> ) urothelial cancer-Reference-Cited by-同舟云学术

Survival after neoadjuvant/induction combination immunotherapy vs combination platinum‐based chemotherapy for locally advanced (Stage III ) urothelial cancer

Published:2022-06-10 Issue:11 Volume:151 Page:2004-2011
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Intl Journal of Cancer

Author:

Einerhand Sarah M. H.¹^ORCID,van Dijk Nick²,van Dorp Jeroen²³,de Feijter Jeantine M.²,van Montfoort Maurits L.⁴,van de Kamp Maaike W.¹,Schaake Eva E.⁵,Boellaard Thierry N.⁶,Hendricksen Kees¹,van der Heijden Michiel S.²³,van Rhijn Bas W. G.¹⁷

Affiliation:

1. Department of Surgical Oncology (Urology) Netherlands Cancer Institute Amsterdam The Netherlands

2. Department of Medical Oncology Netherlands Cancer Institute Amsterdam The Netherlands

3. Department of Molecular Carcinogenesis Netherlands Cancer Institute Amsterdam The Netherlands

4. Department of Pathology Netherlands Cancer Institute Amsterdam The Netherlands

5. Department of Radiation Oncology Netherlands Cancer Institute Amsterdam The Netherlands

6. Department of Radiology Netherlands Cancer Institute Amsterdam The Netherlands

7. Department of Urology Caritas St Josef Medical Center, University of Regensburg Regensburg Germany

Funder

Bristol-Myers Squibb

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.34125

Reference13 articles.

1. Contemporary update on neoadjuvant therapy for bladder cancer

2. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines

3. Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer—Results of a nationwide population-based study

4. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

5. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of neoadjuvant combination immunotherapy in surgically resectable malignant solid tumors: a systematic review and meta-analysis;Expert Review of Anticancer Therapy;2024-03-04

2. A bibliometric insight into neoadjuvant chemotherapy in bladder cancer: trends, collaborations, and future avenues;Frontiers in Immunology;2024-02-19

3. Cuproptosis: Mechanism, role, and advances in urological malignancies;Medicinal Research Reviews;2024-02

4. Targeted therapies in bladder cancer: signaling pathways, applications, and challenges;MedComm;2023-12

5. Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17;Journal of Clinical Oncology;2023-11-20